“…If successful, t‐PBM could significantly improve the quality of life for patients with OCD. Moreover, the safety, low cost, and effectiveness of t‐PBM in other neuropsychiatric disorders (Ahrabi et al., 2022; Caldieraro & Cassano, 2019; Cassano et al., 2015, 2018, 2022; Dos Santos Cardoso et al., 2020; Liebert et al., 2021; Lopes Martins et al., 2021; Mannu et al., 2019; Naeser et al., 2014; O'Donnell et al., 2022; Poiani et al., 2018; Vieira, Gersten, et al., 2023; Vieira, Iosifescu, et al., 2023) as well as its ability to modulate inflammation (Choi et al., 2012; de Barros Silva et al., 2022; de Brito et al., 2022; De Marchi et al., 2021; Esteves et al., 2022; Guo et al., 2021; Ketz et al., 2017; Li, Liang, et al., 2020; Lima et al., 2014; Lu et al., 2017; Ryu et al., 2022; Shaikh‐Kader et al., 2021; Tao et al., 2021; Wang et al., 2021; Wu et al., 2022; Zheng et al., 2021) suggest that t‐PBM could be a valuable addition to the current treatment options for OCD.…”